Add like
Add dislike
Add to saved papers

The hepatitis C virus NS3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.

AIDS 2016 September 21
OBJECTIVES: The Q80K polymorphism is a naturally occurring resistance-associated variant (RAV) in the hepatitis C virus (HCV) NS3 region and is likely transmissible between hosts. This study describes the Q80K origin and prevalence among HCV risk groups in the Netherlands and examines whether Q80K is linked to specific transmission networks.

DESIGN AND METHODS: Stored blood samples from HCV genotype 1a infected patients were used for PCR and sequencing to reconstruct the NS3 maximum likelihood phylogeny. The most recent common ancestor (MRCA) was estimated with a coalescent-based model within a Bayesian statistical framework.

RESULTS: Study participants (n = 150) were either men who have sex with men (MSM, 39%), people who inject drugs (17%), or patients with other (15%) or unknown/unreported (29%) risk behavior. Overall 45% was coinfected with HIV. Q80K was present in 36% (95% CI 28-44%) of patients throughout the sample collection period (2000-2015) and was most prevalent in MSM (52%, 95% CI 38-65%). Five MSM-specific transmission clusters were identified, of which 3 exclusively contained sequences with Q80K. The HCV-1a MRCA in the Netherlands was estimated in 1914 (95% higher posterior density (HPD) 1879-1944) and Q80K originated in 1957 (95% HPD 1942-1970) within HCV-1a clade I. All Q80K lineages could be traced back to this single origin.

CONCLUSIONS: Q80K is a highly stable and transmissible RAV and was present in a large part of Dutch HIV-coinfected MSM. The introduction and expansion of Q80K variants in this key population suggest a founder effect, potentially jeopardizing future treatment with simeprevir.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app